10 results about "Enzyme immunoassays" patented technology

The embodiment of the invention relates to a to-be-detected item typesetting method and device, electronic equipment and a storage medium, and the method comprises the steps: under the condition that a target set type is an enzyme immunoassay item set, according to preset enzyme immunoassay strategy information and item names corresponding to all to-be-detected items, setting the to-be-detected items according to the preset enzyme immunoassay strategy information; performing layout sorting on each experiment number corresponding to the plurality of items to be detected, and adding a fixed position before the first experiment number and / or after the last experiment number of each item to be detected, so as to generate a first layout file suitable for the microplate reader; under the condition that the target set type is a fixed electrophoresis type item set, according to preset electrophoresis typesetting information, item names corresponding to all the to-be-detected items and the number of experiment numbers contained in all the to-be-detected items, experiment numbers contained in all the to-be-detected items are distributed, and generating a second layout file suitable for the immunofixation electrophoresis apparatus. The processing efficiency of to-be-detected items can be improved, and the risk of manual operation errors is reduced.

A method for determining the indication for the prevention of persistent AR in the form of problem-based learning in primary school children, consisting of determining the body mass index (BMI, kg / m 2 ) within the range of +1 SDS or more, taking into account the age and sex of the child and IL 1β using the enzyme immunoassay method; with IL 1β equal to or more than 0.029 pg / ml, a child with overweight / obesity is classified as being at high risk for the development of persistent AR, requiring prevention in the form of problem-based learning.

1. The name of the design product: enzyme label analyzer (DR-8000 series). 2. The use of the design product: a medical testing instrument for enzyme immunoassay. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Disclosed is an antibody which binds to a symmetrically dimethylated arginine analyte that can be used to detect a symmetrically dimethylated arginine analyte in a sample, such as in a homogeneous enzyme immunoassay method.

The utility model discloses an enzyme -free diagnosis reagent detection is placed with rack relates to enzyme -free diagnosis reagent technical field, and the both sides of base are equipped with clamping plate symmetry, and the both sides of clamping plate are equipped with the frame between corresponding, frame includes upper fixed plate, middle fixed plate and lower fixed plate, and upper fixed plate and middle fixed plate are equipped with the card hole of accommodating test tube respectively, and the upper portion of lower fixed plate is equipped with the card slot of being suitable for the bottom of test tube, and the upper portion of upper fixed plate is equipped with cover, and the top of upper fixed plate is equipped with a plurality of fixed column, and cover is equipped with the insertion hole of being suitable for a plurality of fixed column. The design of multilayer fixed plate cooperation card hole, card slot can carry out multidirectional steady limit from the upper portion, the middle and the bottom of test tube, effectively prevent test tube from toppling or falling in the detection process because of the collision, the shaking, and the falling; cover can be stably covered on upper fixed plate through the cooperation of fixed column and insertion hole, can block the dust, impurity of outside and fall into test tube, guarantee reagent not to be contaminated.

The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42 / 40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS / MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42 / 40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.

The utility model discloses an incubation module and full -automatic enzyme free instrument, wherein the incubation module includes the incubator cover, the incubation module is equipped with the placement area for placing the incubator cover, the incubator cover includes first cover, second cover, counterweight spare and heating assembly, second cover with first cover is connected to and is enclosed and forms the accommodation cavity, the counterweight spare is located in the accommodation cavity, the heating assembly includes heating spare and conducting structure, heating spare is located in the accommodation cavity, conducting structure with heating spare is connected, and at least part of conducting structure stretches out the accommodation cavity outside, when the incubator cover is located in the placement area, conducting structure can with external circuit guide to with heating spare heating. It is designed to improve the incubation efficiency while reducing the production of condensate during the incubation process, also avoid the risk of incubator cover being corroded.

Disclosed herein are antibodies that specifically bind to a methotrexate analyte. Such antibodies can be used to detect a methotrexate analyte in a sample, such as in a homogeneous enzyme immunoassay method. Hapten structures to elicit such antibodies are also described. Conjugates useful in immunoassays that use such antibodies are also described.

The invention relates to the technical field of enzyme immunoassay, in particular to an enzyme immunoassay full-automatic sample adding real-time monitoring device which comprises an enzyme immunoassay workstation and a sample adding module. A plurality of groups of sample adding pipes which are arranged side by side are mounted at the bottom of the sample adding arm, and sample adding needle heads for sucking samples are mounted at the bottoms of the sample adding pipes; a liquid blowing mechanism is further arranged on the outer side of the sample adding pipe, a lifting mechanism is fixedly connected above the liquid blowing mechanism, and a guide mechanism is fixedly connected below the liquid blowing mechanism; when the sampling needle head injects liquid for the last time, blowing equipment is started, air enters the hollow gear disc through the L-shaped fixing pipe and the fixing ring and is discharged from an exhaust port in the bottom of the liquid blowing pipe, liquid blowing is carried out on the bottom of the sampling needle head, and residual liquid is assisted to drop to a detection hole; meanwhile, the driving motor is started to drive the driving gear to rotate, and the liquid blowing pipe is driven to rotate through meshing transmission of the driving gear, the driven gear and the hollow gear disc, so that multi-angle blowing of the bottom of the sampling needle head is realized, and sufficient dripping of residual liquid is ensured.

This specification discloses antibodies that specifically bind to methotrexate analyte. Such antibodies can be used to detect methotrexate analyte in samples in homogeneous enzyme immunoassays and the like. Hapten structures for inducing such antibodies are also described. Furthermore, conjugates useful for immunoassays using such antibodies are also described.